There were 649 press releases posted in the last 24 hours and 437,942 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Summit Enters Into Licence and Commercialisation Agreement With Eurofarma for Latin American Rights to Ridinilazole, Summit’s Precision Antibiotic in Development for the Treatment of CDI

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image